Nervous system effects of antituberculosis therapy.
Nervous system toxicity with current antituberculosis pharmacotherapy is relatively uncommon, although the frequency of the usage of antituberculosis therapy requires that physicians be aware of such toxicity. Antituberculosis therapy manifests both central and peripheral nervous system effects, which may compromise patient compliance. Among the traditional forms of first-line antituberculosis therapy, isoniazid is most often associated with nervous system effects, most prominently peripheral neuropathy, psychosis and seizures. Adverse events are reported with other antituberculosis therapies, the most prominent being optic neuropathy with ethambutol and ototoxicity and neuromuscular blockade with aminoglycosides. The second-line agent with the most adverse effects is cycloserine, with psychosis and seizures, the psychosis in particular limiting its usage. Fluoroquinolones are rare causes of seizures and delirium. Newer forms of therapy are under development, but to date no significant neurotoxicity is documented with these agents. Future needs include the development of surveillance mechanisms to increase recognition of nervous system toxicities. It is also hoped that the development of new pharmacogenomic assays will help with the identification of patients at risk for these toxicities.
Kass
Joseph S
JS
Baylor College of Medicine, Houston, Texas 77030, USA. kass@bcm.edu
Shandera
Wayne X
WX
D000818:Animals; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000506:poisoning / Q000627:therapeutic use; D002490:Central Nervous System / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D009169:Mycobacterium tuberculosis; D009422:Nervous System Diseases / Q000139:chemically induced*; D017933:Peripheral Nervous System / Q000187:drug effects*; D014376:Tuberculosis / Q000188:drug therapy*
D000995:Antitubercular Agents